EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political support erode.

Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

The European Medicines Agency has recommended the approval of lenacapavir, a new bi-annual injectable drug aimed at ...

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

TODAY i have some great news to share. Besides the fact that last week was the King's Birthday, something exciting was happening in the HIV ...

LONDON — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, ...

The results suggest the possibility of a vaccine for HIV/AIDS, which killed more than half a million people last year.